This gene, CYP4F3, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. The enzyme starts the process of inactivating and degrading leukotriene B4, a pot... See more...

Aliases for CYP4F3 Gene

Aliases for CYP4F3 Gene

  • Cytochrome P450 Family 4 Subfamily F Member 3 2 3 5
  • Cytochrome P450, Subfamily IVF, Polypeptide 3 (Leukotriene B4 Omega Hydroxylase) 2 3
  • Cytochrome P450, Family 4, Subfamily F, Polypeptide 3 2 3
  • Docosahexaenoic Acid Omega-Hydroxylase CYP4F3 3 4
  • 20-Hydroxyeicosatetraenoic Acid Synthase 3 4
  • Leukotriene-B(4) Omega-Hydroxylase 2 3 4
  • Leukotriene-B(4) 20-Monooxygenase 2 3 4
  • Cytochrome P450-LTB-Omega 3 4
  • Cytochrome P450 4F3 3 4
  • 20-HETE Synthase 3 4
  • CYPIVF3 3 4
  • CYP4F 2 3
  • LTB4H 3 4
  • Leukotriene B4 Omega Hydroxylase 3
  • Leukotriene-B4 20-Monooxygenase 3
  • Cytochrome P-450 3
  • EC 1.14.14.79 4
  • EC 1.14.14.94 4
  • EC 1.14.14.1 4
  • CYP4F3 5
  • CPF3 3

External Ids for CYP4F3 Gene

Previous HGNC Symbols for CYP4F3 Gene

  • LTB4H

Previous GeneCards Identifiers for CYP4F3 Gene

  • GC19P016130
  • GC19P016013
  • GC19P015482
  • GC19P015612
  • GC19P015751
  • GC19P015320
  • GC19P015615

Summaries for CYP4F3 Gene

Entrez Gene Summary for CYP4F3 Gene

  • This gene, CYP4F3, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. The enzyme starts the process of inactivating and degrading leukotriene B4, a potent mediator of inflammation. This gene is part of a cluster of cytochrome P450 genes on chromosome 19. Another member of this family, CYP4F8, is approximately 18 kb away. Several transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Apr 2019]

GeneCards Summary for CYP4F3 Gene

CYP4F3 (Cytochrome P450 Family 4 Subfamily F Member 3) is a Protein Coding gene. Diseases associated with CYP4F3 include Trichuriasis and Neuropathy, Hereditary Sensory And Autonomic, Type Ic. Among its related pathways are Cytochrome P450 - arranged by substrate type and HETE and HPETE biosynthesis and metabolism. Gene Ontology (GO) annotations related to this gene include iron ion binding and oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen. An important paralog of this gene is CYP4F2.

UniProtKB/Swiss-Prot Summary for CYP4F3 Gene

  • A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins) (PubMed:8486631, PubMed:9675028, PubMed:11461919, PubMed:15145985, PubMed:16547005, PubMed:16820285, PubMed:18182499, PubMed:18065749, PubMed:18577768). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:9675028). May play a role in inactivation of proinflammatory and anti-inflammatory oxylipins during the resolution of inflammation (PubMed:8486631, PubMed:9675028, PubMed:11461919, PubMed:15145985, PubMed:15364545, PubMed:16547005, PubMed:16820285, PubMed:18182499, PubMed:18065749, PubMed:18577768).
  • [Isoform CYP4F3A]: Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of oxylipins in myeloid cells, displaying higher affinity for arachidonate metabolite leukotriene B4 (LTB4) (PubMed:8486631, PubMed:9675028, PubMed:11461919, PubMed:15364545). Inactivates LTB4 via three successive oxidative transformations to 20-hydroxy-LTB4, then to 20-oxo-LTB4 and to 20-carboxy-LTB4 (PubMed:9675028). Has omega-hydroxylase activity toward long-chain fatty acid epoxides with preference for 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate (EET) and 9,10-epoxyoctadecanoate (PubMed:15145985). Omega-hydroxylates monohydroxy polyunsaturated fatty acids (PUFAs), including hydroxyeicosatetraenoates (HETEs) and hydroxyeicosapentaenoates (HEPEs), to dihydroxy compounds (PubMed:15364545, PubMed:9675028). Contributes to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acid, thereby initiating chain shortening (PubMed:18182499). Has low hydroxylase activity toward PUFAs (PubMed:18577768, PubMed:11461919).
  • [Isoform CYP4F3B]: Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of polyunsaturated fatty acids (PUFAs) (PubMed:11461919, PubMed:16820285, PubMed:18577768). Participates in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure (PubMed:11461919, PubMed:16820285, PubMed:18577768). Has high omega-hydroxylase activity toward other PUFAs, including eicosatrienoic acid (ETA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (PubMed:16820285, PubMed:18577768). Can also catalyze the oxidation of the penultimate carbon (omega-1 oxidation) of PUFAs with lower efficiency (PubMed:18577768). Contributes to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid and hexacosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acids, thereby initiating chain shortening (PubMed:16547005, PubMed:18182499). Omega-hydroxylates long-chain 3-hydroxy fatty acids, likely initiating the oxidative conversion to the corresponding 3-hydroxydicarboxylic fatty acids (PubMed:18065749). Has omega-hydroxylase activity toward long-chain fatty acid epoxides with preference for 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate (EET) and 9,10-epoxyoctadecanoate (PubMed:15145985).

Tocris Summary for CYP4F3 Gene

  • Hydroxylases are enzymes that catalyze the addition of hydroxyl groups to substrates during oxidation reactions. This diverse group of enzymes includes tryptophan hydroxylase (E.C. 1.14.16.4), steroid 11-beta hydroxylase (E.C. 1.14.15.4), and LTB4 omega-hydroxylase (E.C. 1.14.13.30).

Gene Wiki entry for CYP4F3 Gene

No data available for CIViC Summary , PharmGKB "VIP" Summary , Rfam classification and piRNA Summary for CYP4F3 Gene

Genomics for CYP4F3 Gene

GeneHancer (GH) Regulatory Elements Pubs

Promoters and enhancers for CYP4F3 Gene
GeneHancer (GH) Identifier GH Type GH
Score
GH Sources Gene Association Score Total Score TSS distance (kb) Number of Genes Away Size (kb) Transcription Factor
Binding Sites
Gene Targets
GH19J015639 Promoter/Enhancer 1.5 EPDnew FANTOM5 ENCODE 263 +0.1 106 3 IKZF1 SSRP1 ZMYM3 CEBPA ATF3 NFIC YY1 REST FOXA1 KLF11 CYP4F3 CYP4F12 HSH2D CYP4F10P OR10H5 RAB8A CLEC4OP BRD4 AKAP8 lnc-CYP4F12-1
GH19J015584 Enhancer 0.9 ENCODE 5.1 -56.1 -56082 0.1 ZNF654 ZIC2 CTCF REST ZBTB7B THAP11 SMAD4 SAP130 RAD21 SMC3 HSALNG0124384 CHERP AKAP8 C19orf44 CYP4F12 ZNF333 CYP4F11 OR10H5 BRD4 CYP4F3
GH19J015606 Enhancer 0.7 Ensembl 5.5 -33.9 -33896 1.6 NCOR1 NFIC HES1 TAL1 SMARCA4 FOXM1 HDAC2 ZEB2 TCF12 MTA2 lnc-PGLYRP2-1 piR-36531-010 piR-33422-204 piR-58297-235 CYP4F10P CLEC4OP CYP4F3 CYP4F24P CYP4F8 piR-41525-324
GH19J015668 Enhancer 0.3 Ensembl 10.5 +28.7 28704 2.4 REST MIER2 CYP4F12 CYP4F24P CYP4F3 CYP4F10P ENSG00000269044 lnc-OR7C2-1
GH19J015611 Promoter 0.3 Ensembl 8.6 -29.1 -29096 0.4 AD000091 ENSG00000267135 RPL23AP2 lnc-CYP4F8-1 lnc-PGLYRP2-3 CYP4F3 CYP4F8 HSALNG0124383 CYP4F22 lnc-OR7C2-1
- Elite GeneHancer and/or Elite GeneHancer-gene association Download GeneHancer data from 2017 publication | Request up-to-date GeneHancer data (full dataset)

GeneHancers around CYP4F3 on the GeneHancer Hub at the UCSC Golden Path

Cistromic (ChIP-Seq) regulation report from SPP (The Signaling Pathways Project) for CYP4F3

Top Transcription factor binding sites by QIAGEN in the CYP4F3 gene promoter:
  • AP-1
  • Brachyury
  • c-Fos
  • c-Jun
  • CREB
  • deltaCREB
  • Elk-1
  • FosB
  • NRSF form 1
  • NRSF form 2

Genomic Locations for CYP4F3 Gene

Latest Assembly
chr19:15,640,897-15,662,825
(GRCh38/hg38)
Size:
21,929 bases
Orientation:
Plus strand

Previous Assembly
chr19:15,751,707-15,773,635
(GRCh37/hg19 by Entrez Gene)
Size:
21,929 bases
Orientation:
Plus strand

chr19:15,751,707-15,773,635
(GRCh37/hg19 by Ensembl)
Size:
21,929 bases
Orientation:
Plus strand

Genomic View for CYP4F3 Gene

Genes around CYP4F3 on UCSC Golden Path with GeneCards custom track

Cytogenetic band:
CYP4F3 Gene in genomic location: bands according to Ensembl, locations according to GeneLoc (and/or Entrez Gene and/or Ensembl if different)
Genomic Location for CYP4F3 Gene
GeneLoc Logo Genomic Neighborhood Exon StructureGene Density

RefSeq DNA sequence for CYP4F3 Gene

Proteins for CYP4F3 Gene

  • Protein details for CYP4F3 Gene (UniProtKB/Swiss-Prot)

    Protein Symbol:
    Q08477-CP4F3_HUMAN
    Recommended name:
    Cytochrome P450 4F3
    Protein Accession:
    Q08477
    Secondary Accessions:
    • B7Z8Z3
    • O60634
    • Q5U740

    Protein attributes for CYP4F3 Gene

    Size:
    520 amino acids
    Molecular mass:
    59847 Da
    Cofactor:
    Name=heme; Xref=ChEBI:CHEBI:30413;
    Quaternary structure:
    No Data Available

    Alternative splice isoforms for CYP4F3 Gene

    UniProtKB/Swiss-Prot:

neXtProt entry for CYP4F3 Gene

Post-translational modifications for CYP4F3 Gene

  • Modification sites at PhosphoSitePlus
  • Modification sites at neXtProt

No data available for DME Specific Peptides for CYP4F3 Gene

Domains & Families for CYP4F3 Gene

Gene Families for CYP4F3 Gene

HGNC:
IUPHAR :
Human Protein Atlas (HPA):
  • Enzymes
  • Predicted intracellular proteins

Protein Domains for CYP4F3 Gene

InterPro:
Blocks:
  • Group II E-class P450 signature

Suggested Antigen Peptide Sequences for CYP4F3 Gene

GenScript: Design optimal peptide antigens:
  • cDNA, FLJ79035, highly similar to Cytochrome P450 4F2 (EC 1.14.13.30) (B7Z8Z3_HUMAN)
  • Leukotriene-B(4) 20-monooxygenase 2 (CP4F3_HUMAN)

Graphical View of Domain Structure for InterPro Entry

Q08477

UniProtKB/Swiss-Prot:

CP4F3_HUMAN :
  • Belongs to the cytochrome P450 family.
Family:
  • Belongs to the cytochrome P450 family.
genes like me logo Genes that share domains with CYP4F3: view

Function for CYP4F3 Gene

Molecular function for CYP4F3 Gene

UniProtKB/Swiss-Prot Function:
A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins) (PubMed:8486631, PubMed:9675028, PubMed:11461919, PubMed:15145985, PubMed:16547005, PubMed:16820285, PubMed:18182499, PubMed:18065749, PubMed:18577768). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:9675028). May play a role in inactivation of proinflammatory and anti-inflammatory oxylipins during the resolution of inflammation (PubMed:8486631, PubMed:9675028, PubMed:11461919, PubMed:15145985, PubMed:15364545, PubMed:16547005, PubMed:16820285, PubMed:18182499, PubMed:18065749, PubMed:18577768).
UniProtKB/Swiss-Prot Function:
[Isoform CYP4F3A]: Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of oxylipins in myeloid cells, displaying higher affinity for arachidonate metabolite leukotriene B4 (LTB4) (PubMed:8486631, PubMed:9675028, PubMed:11461919, PubMed:15364545). Inactivates LTB4 via three successive oxidative transformations to 20-hydroxy-LTB4, then to 20-oxo-LTB4 and to 20-carboxy-LTB4 (PubMed:9675028). Has omega-hydroxylase activity toward long-chain fatty acid epoxides with preference for 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate (EET) and 9,10-epoxyoctadecanoate (PubMed:15145985). Omega-hydroxylates monohydroxy polyunsaturated fatty acids (PUFAs), including hydroxyeicosatetraenoates (HETEs) and hydroxyeicosapentaenoates (HEPEs), to dihydroxy compounds (PubMed:15364545, PubMed:9675028). Contributes to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acid, thereby initiating chain shortening (PubMed:18182499). Has low hydroxylase activity toward PUFAs (PubMed:18577768, PubMed:11461919).
UniProtKB/Swiss-Prot Function:
[Isoform CYP4F3B]: Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of polyunsaturated fatty acids (PUFAs) (PubMed:11461919, PubMed:16820285, PubMed:18577768). Participates in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure (PubMed:11461919, PubMed:16820285, PubMed:18577768). Has high omega-hydroxylase activity toward other PUFAs, including eicosatrienoic acid (ETA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (PubMed:16820285, PubMed:18577768). Can also catalyze the oxidation of the penultimate carbon (omega-1 oxidation) of PUFAs with lower efficiency (PubMed:18577768). Contributes to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid and hexacosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acids, thereby initiating chain shortening (PubMed:16547005, PubMed:18182499). Omega-hydroxylates long-chain 3-hydroxy fatty acids, likely initiating the oxidative conversion to the corresponding 3-hydroxydicarboxylic fatty acids (PubMed:18065749). Has omega-hydroxylase activity toward long-chain fatty acid epoxides with preference for 8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate (EET) and 9,10-epoxyoctadecanoate (PubMed:15145985).
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=an organic molecule + O2 + reduced [NADPH--hemoprotein reductase] = an alcohol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:17149, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:30879, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:142491; EC=1.14.14.1; Evidence={ECO:0000269|PubMed:11461919, ECO:0000269|PubMed:16820285, ECO:0000269|PubMed:8486631};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=leukotriene B4 + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-leukotriene B4 + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:22176, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57460, ChEBI:CHEBI:57461, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; EC=1.14.14.94; Evidence={ECO:0000269|PubMed:11461919, ECO:0000269|PubMed:15364545, ECO:0000269|PubMed:8486631, ECO:0000269|PubMed:9675028};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=20-hydroxy-leukotriene B4 + O2 + reduced [NADPH--hemoprotein reductase] = 20-oxo-leukotriene B4 + H(+) + 2 H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:48668, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57460, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:90720; Evidence={ECO:0000269|PubMed:9675028};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=20-oxo-leukotriene B4 + O2 + reduced [NADPH--hemoprotein reductase] = 20-carboxy-leukotriene B4 + 2 H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:48672, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:90720, ChEBI:CHEBI:90722; Evidence={ECO:0000269|PubMed:9675028};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z)-eicosatrienoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:50164, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:78043, ChEBI:CHEBI:132026; Evidence={ECO:0000269|PubMed:18577768};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39755, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76624; Evidence={ECO:0000269|PubMed:11461919, ECO:0000269|PubMed:15364545, ECO:0000269|PubMed:18577768};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 19-hydroxy-(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39787, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:76636; Evidence={ECO:0000269|PubMed:18577768};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39791, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:76639; Evidence={ECO:0000269|PubMed:18577768};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 21-hydroxy-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:50088, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:77016, ChEBI:CHEBI:132025; Evidence={ECO:0000269|PubMed:18577768};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 22-hydroxy-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:40155, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:77015, ChEBI:CHEBI:77016; EC=1.14.14.79; Evidence={ECO:0000269|PubMed:18577768};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53572, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:84025, ChEBI:CHEBI:137474; Evidence={ECO:0000269|PubMed:15145985};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53576, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76625, ChEBI:CHEBI:137475; Evidence={ECO:0000269|PubMed:15145985};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=14,15-epoxy-(5Z,8Z,11Z)-eicosatrienoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-14,15-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53580, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:84024, ChEBI:CHEBI:137476; Evidence={ECO:0000269|PubMed:15145985};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=12,13-epoxy-(9Z)-octadecenoate + O2 + reduced [NADPH--hemoprotein reductase] = 18-hydroxy-12,13-epoxy-(9Z)-octadecenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53568, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:84026, ChEBI:CHEBI:137469; Evidence={ECO:0000269|PubMed:15145985};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=9,10-epoxy-(12Z)-octadecenoate + O2 + reduced [NADPH--hemoprotein reductase] = 18-hydroxy-9,10-epoxy-(12Z)-octadecenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53564, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:84023, ChEBI:CHEBI:137467; Evidence={ECO:0000269|PubMed:15145985};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=9,10-epoxyoctadecanoate + O2 + reduced [NADPH--hemoprotein reductase] = 18-hydroxy-9,10-epoxy-octadecanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:53560, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:85195, ChEBI:CHEBI:137457; Evidence={ECO:0000269|PubMed:15145985};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(12R)-hydroxy-(9Z)-octadecenoate + O2 + reduced [NADPH--hemoprotein reductase] = (12R),18-dihydroxy-(9Z)-octadecenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49384, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:91295, ChEBI:CHEBI:91300; Evidence={ECO:0000269|PubMed:9675028};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=12-hydroxyoctadecanoate + O2 + reduced [NADPH--hemoprotein reductase] = 12,18-dihydroxyoctadecanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49376, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:84201, ChEBI:CHEBI:91294; Evidence={ECO:0000269|PubMed:9675028};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=5-hydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 5,20-dihydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:48656, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:65341, ChEBI:CHEBI:90715; Evidence={ECO:0000269|PubMed:15364545, ECO:0000269|PubMed:9675028};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=8-hydroxy-(5Z,9E,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 8,20-dihydroxy-(5Z,9E,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:48660, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:90716, ChEBI:CHEBI:90717; Evidence={ECO:0000269|PubMed:15364545, ECO:0000269|PubMed:9675028};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=12-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 12,20-dihydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:48664, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:90718, ChEBI:CHEBI:90719; Evidence={ECO:0000269|PubMed:15364545};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=5-hydroxy-(6E,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 5,20-dihydroxy-(6E,8Z,11Z,14Z,17Z)-eicosapentaenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49380, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:90737, ChEBI:CHEBI:91301; Evidence={ECO:0000269|PubMed:9675028};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=lipoxin A4 + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-lipoxin A4 + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:48648, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:67026, ChEBI:CHEBI:90707; Evidence={ECO:0000269|PubMed:15364545};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=lipoxin B4 + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-lipoxin B4 + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:48652, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:67031, ChEBI:CHEBI:90711; Evidence={ECO:0000269|PubMed:15364545, ECO:0000269|PubMed:9675028};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=22-hydroxydocosanoate + O2 + reduced [NADPH--hemoprotein reductase] = 22-oxodocosanoate + H(+) + 2 H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39055, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76298, ChEBI:CHEBI:76304; Evidence={ECO:0000269|PubMed:18182499};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=22-oxodocosanoate + O2 + reduced [NADPH--hemoprotein reductase] = docosanedioate + 2 H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39043, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76298, ChEBI:CHEBI:76299; Evidence={ECO:0000269|PubMed:18182499};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39755, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76624; Evidence={ECO:0000269|PubMed:11461919, ECO:0000269|PubMed:16820285, ECO:0000269|PubMed:18577768};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 20-hydroxy-(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39791, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:76639; Evidence={ECO:0000269|PubMed:16820285, ECO:0000269|PubMed:18577768};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 22-hydroxy-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:40155, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:77015, ChEBI:CHEBI:77016; EC=1.14.14.79; Evidence={ECO:0000269|PubMed:16820285, ECO:0000269|PubMed:18577768};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=docosanoate + O2 + reduced [NADPH--hemoprotein reductase] = 22-hydroxydocosanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:40079, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:23858, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76304; Evidence={ECO:0000269|PubMed:16547005};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=O2 + reduced [NADPH--hemoprotein reductase] + tetracosanoate = 24-hydroxytetracosanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39719, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:31014, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76610; Evidence={ECO:0000269|PubMed:16547005};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=hexacosanoate + O2 + reduced [NADPH--hemoprotein reductase] = 26-hydroxyhexacosanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:40083, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:31013, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76305; Evidence={ECO:0000269|PubMed:16547005};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=26-hydroxyhexacosanoate + O2 + reduced [NADPH--hemoprotein reductase] = 26-oxohexacosanoate + H(+) + 2 H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39059, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76305, ChEBI:CHEBI:76311; Evidence={ECO:0000269|PubMed:16547005, ECO:0000269|PubMed:18182499};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=26-oxohexacosanoate + O2 + reduced [NADPH--hemoprotein reductase] = 2 H(+) + H2O + hexacosanedioate + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39047, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76311, ChEBI:CHEBI:76312; Evidence={ECO:0000269|PubMed:16547005, ECO:0000269|PubMed:18182499};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=3-hydroxyoctadecanoate + O2 + reduced [NADPH--hemoprotein reductase] = 3,18-dihydroxyoctadecanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39735, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76614, ChEBI:CHEBI:76615; Evidence={ECO:0000269|PubMed:18065749};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=3-hydroxyhexadecanoate + O2 + reduced [NADPH--hemoprotein reductase] = 3,16-dihydroxyhexadecanoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39731, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:63904, ChEBI:CHEBI:76613; Evidence={ECO:0000269|PubMed:18065749};.
UniProtKB/Swiss-Prot BiophysicochemicalProperties:
[Isoform CYP4F3A]: Kinetic parameters: KM=0.64 uM for leukotriene B4 {ECO:0000269|PubMed:9675028}; KM=6.5 uM for 20-hydroxy-leukotriene B4 {ECO:0000269|PubMed:9675028}; KM=0.68 uM for leukotriene B4 {ECO:0000269|PubMed:11461919}; KM=185.6 uM for arachidonate {ECO:0000269|PubMed:11461919}; KM=17.9 uM for lipoxin B4 {ECO:0000269|PubMed:9675028}; KM=25.7 uM for 5-HETE {ECO:0000269|PubMed:9675028}; KM=40.9 uM for 12-HETE {ECO:0000269|PubMed:9675028}; KM=49.5 uM for 5-HEPE {ECO:0000269|PubMed:9675028}; KM=14.2 uM for 12-hydroxyoctadecanoate {ECO:0000269|PubMed:9675028}; KM=22.8 uM for (12R)-hydroxy-(9Z)-octadecenoate {ECO:0000269|PubMed:9675028}; KM=6.3 uM for 9(10)-epoxyoctadecanoate {ECO:0000269|PubMed:15145985}; KM=46.6 uM for 9(10)-epoxy-(12Z)-octadecenoate {ECO:0000269|PubMed:15145985}; KM=61.8 uM for 12(13)-epoxy-(9Z)-octadecenoate {ECO:0000269|PubMed:15145985}; KM=0.6 uM for 22-hydroxydocosanoate {ECO:0000269|PubMed:18182499}; Vmax=34.0 nmol/min/nmol enzyme toward leukotriene B4 {ECO:0000269|PubMed:9675028}; Vmax=66.7 nmol/min/nmol enzyme toward 20-hydroxy-leukotriene B4 {ECO:0000269|PubMed:9675028}; Vmax=32.8 pmol/min/pmol enzyme toward leukotriene B4 {ECO:0000269|PubMed:11461919}; Vmax=11.5 pmol/min/pmol enzyme toward arachidonate {ECO:0000269|PubMed:11461919}; Vmax=38.5 nmol/min/nmol enzyme toward lipoxin B4 {ECO:0000269|PubMed:9675028}; Vmax=21.6 nmol/min/nmol enzyme toward 5-HETE {ECO:0000269|PubMed:9675028}; Vmax=43.2 nmol/min/nmol enzyme toward 12-HETE {ECO:0000269|PubMed:9675028}; Vmax=95.1 nmol/min/nmol enzyme toward 5-HEPE {ECO:0000269|PubMed:9675028}; Vmax=54.5 nmol/min/nmol enzyme toward 12-hydroxyoctadecanoate {ECO:0000269|PubMed:9675028}; Vmax=19.0 nmol/min/nmol enzyme toward (12R)-hydroxy-(9Z)-octadecenoate {ECO:0000269|PubMed:9675028}; Vmax=10.8 nmol/min/nmol enzyme toward 9(10)-epoxyoctadecanoate {ECO:0000269|PubMed:15145985}; Vmax=21.2 nmol/min/nmol enzyme toward 9(10)-epoxy-(12Z)-octadecenoate {ECO:0000269|PubMed:15145985}; Vmax=3 nmol/min/nmol enzyme toward 12(13)-epoxy-(9Z)-octadecenoate {ECO:0000269|PubMed:15145985}; Vmax=0.2 pmol/min/pmol enzyme toward 22-hydroxydocosanoate {ECO:0000269|PubMed:18182499}; pH dependence: Optimum pH is 7.5. {ECO:0000269|PubMed:9675028};
UniProtKB/Swiss-Prot BiophysicochemicalProperties:
[Isoform CYP4F3B]: Kinetic parameters: KM=20.6 uM for leukotriene B4 {ECO:0000269|PubMed:11461919}; KM=22.0 uM for arachidonate {ECO:0000269|PubMed:11461919}; KM=35.7 uM for 9(10)-epoxyoctadecanoate {ECO:0000269|PubMed:15145985}; KM=108.1 uM for 9(10)-epoxy-(12Z)-octadecenoate {ECO:0000269|PubMed:15145985}; KM=100.6 uM for 12(13)-epoxy-(9Z)-octadecenoate {ECO:0000269|PubMed:15145985}; KM=1.6 uM for docosanoate {ECO:0000269|PubMed:16547005}; KM=3.8 uM for tetracosanoate {ECO:0000269|PubMed:16547005}; KM=1.3 uM for hexacosanoate {ECO:0000269|PubMed:16547005}; KM=13.1 uM for 22-hydroxydocosanoate {ECO:0000269|PubMed:18182499}; KM=5.2 uM for 26-hydroxyhexacosanoate {ECO:0000269|PubMed:18182499}; Vmax=23.3 pmol/min/pmol enzyme toward leukotriene B4 {ECO:0000269|PubMed:11461919}; Vmax=13.3 pmol/min/pmol enzyme toward arachidonate {ECO:0000269|PubMed:11461919}; Vmax=13.2 nmol/min/nmol enzyme toward 9(10)-epoxyoctadecanoate {ECO:0000269|PubMed:15145985}; Vmax=15.02 nmol/min/nmol enzyme toward 9(10)-epoxy-(12Z)-octadecenoate {ECO:0000269|PubMed:15145985}; Vmax=3.93 nmol/min/nmol enzyme toward 12(13)-epoxy-(9Z)-octadecenoate {ECO:0000269|PubMed:15145985}; Vmax=5.0 pmol/min/pmol enzyme toward docosanoate {ECO:0000269|PubMed:16547005}; Vmax=9.8 pmol/min/pmol enzyme toward tetracosanoate {ECO:0000269|PubMed:16547005}; Vmax=2.2 pmol/min/pmol enzyme toward hexacosanoate {ECO:0000269|PubMed:16547005}; Vmax=0.3 pmol/min/pmol enzyme toward 22-hydroxydocosanoate {ECO:0000269|PubMed:18182499}; Vmax=0.8 pmol/min/pmol enzyme toward 26-hydroxyhexacosanoate {ECO:0000269|PubMed:18182499}; Note=The omega-hydroxylation of VLCFAs follows dual-enzyme Michaelis-Menten kinetics, suggesting simultaneous binding of two substrate molecules. The high affinity Michaelis-Menten constants are shown. {ECO:0000269|PubMed:16547005};
UniProtKB/Swiss-Prot EnzymeRegulation:
Inhibited by carbon monoxide (CO).
GENATLAS Biochemistry:
cytochrome p450,subfamily IVF,polypeptide 3,59.8kDa,expressed in granulocytes,catalyzing the inactivation of leukotrienne beta 4 with two forms resulting from tissue specific splicing and alternative promoters

Enzyme Numbers (IUBMB) for CYP4F3 Gene

Phenotypes From GWAS Catalog for CYP4F3 Gene

Gene Ontology (GO) - Molecular Function for CYP4F3 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0004497 monooxygenase activity TAS 8486631
GO:0005506 iron ion binding IEA --
GO:0008391 arachidonic acid monooxygenase activity IBA 21873635
GO:0016491 oxidoreductase activity IEA --
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen IEA --
genes like me logo Genes that share ontologies with CYP4F3: view
genes like me logo Genes that share phenotypes with CYP4F3: view

Inhibitory RNAs for research

  • Search GeneCopoeia for shRNA, lentivirus and/or AAV clone products for CYP4F3

No data available for Human Phenotype Ontology , Animal Models , Transcription Factor Targets and HOMER Transcription for CYP4F3 Gene

Localization for CYP4F3 Gene

Subcellular locations from UniProtKB/Swiss-Prot for CYP4F3 Gene

Endoplasmic reticulum membrane. Single-pass membrane protein. Microsome membrane. Single-pass membrane protein.

Subcellular locations from

COMPARTMENTS
Extracellular space Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi Apparatus Nucleus Mitochondrion 0 1 2 3 4 5 Confidence
COMPARTMENTS Subcellular localization image for CYP4F3 gene
Compartment Confidence
plasma membrane 2
extracellular 2
peroxisome 2
nucleus 2
endoplasmic reticulum 2
cytoskeleton 1
mitochondrion 1
cytosol 1
lysosome 1
golgi apparatus 0

Gene Ontology (GO) - Cellular Components for CYP4F3 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0005783 endoplasmic reticulum IEA --
GO:0005789 endoplasmic reticulum membrane TAS --
GO:0016020 membrane IEA --
GO:0016021 integral component of membrane IEA --
GO:0031090 organelle membrane IEA --
genes like me logo Genes that share ontologies with CYP4F3: view

No data available for Subcellular locations from the Human Protein Atlas (HPA) for CYP4F3 Gene

Pathways & Interactions for CYP4F3 Gene

genes like me logo Genes that share pathways with CYP4F3: view

Pathways by source for CYP4F3 Gene

2 KEGG pathways for CYP4F3 Gene
1 GeneGo (Thomson Reuters) pathway for CYP4F3 Gene
  • HETE and HPETE biosynthesis and metabolism

UniProtKB/Swiss-Prot Q08477-CP4F3_HUMAN

  • Pathway: [Isoform CYP4F3A]: Lipid metabolism; leukotriene B4 degradation.
  • Pathway: Lipid metabolism; arachidonate metabolism.

Gene Ontology (GO) - Biological Process for CYP4F3 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0006629 lipid metabolic process IEA --
GO:0006631 fatty acid metabolic process IEA --
GO:0006690 icosanoid metabolic process TAS --
GO:0006691 leukotriene metabolic process TAS --
GO:0019369 arachidonic acid metabolic process IEA --
genes like me logo Genes that share ontologies with CYP4F3: view

No data available for SIGNOR curated interactions for CYP4F3 Gene

Drugs & Compounds for CYP4F3 Gene

(14) Drugs for CYP4F3 Gene - From: DrugBank, HMDB, Tocris, and Novoseek

Name Status Disease Links Group Role Mechanism of Action Clinical Trials
Ponesimod Approved, Investigational Pharma Enzyme, substrate 0
Carbon monoxide Approved, Investigational Pharma 194
Oxygen Approved, Vet_approved Pharma 0
Water Approved Pharma 0
Metyrapone Approved, Investigational Pharma 11-beta hydroxylase inhibitor 15

(6) Additional Compounds for CYP4F3 Gene - From: HMDB

Name Synonyms Role CAS Number PubChem IDs PubMed IDs
12(S)-Leukotriene B4
  • 12(S)-Leukotriene b4
  • 12-Epi-LTB4
  • 12S-LTB4
  • 5S,12S-Dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid
  • 5S,12S-Dihydroxy-6Z,8E,10E,14Z-eicosatetraenoate
83709-73-3
12-Keto-tetrahydro-leukotriene B4
  • 12-Keto-10,11,14,15-tetrahydro-LTB4
  • 5S-Hydroxy-12-keto-6Z,8E-eicosadienoate
  • 5S-Hydroxy-12-keto-6Z,8E-eicosadienoic acid
18-Hydroxyarachidonic acid
  • (18R)-HETE
  • (5Z,8Z,11Z,14Z,18R)-18-Hydroxyicosatetraenoic acid
  • 18(R)-Hydroxyeicosatetraenoic acid
  • Hydroxyarachidonic acid
  • (5Z,8Z,11Z,14Z,18R)-18-Hydroxyicosatetraenoate
124411-81-0
20-Hydroxyeicosatetraenoic acid
  • (5Z,8Z,11Z,14Z)-20-Hydroxyicosa-5,8,11,14-tetraenoic acid
  • 20-Hydroxy arachidonic acid
  • 20-Hydroxyarachidonic acid
  • 20-Hydroxyicosatetraenoic acid
  • (5Z,8Z,11Z,14Z)-20-Hydroxyicosa-5,8,11,14-tetraenoate
79551-86-3
20-Hydroxy-leukotriene B4
  • (6Z,8E,10E,14Z)-(5S,12R)-5,12,20-Trihydroxyeicosa-6,8,10,14-tetraenoate
  • (6Z,8E,10E,14Z)-(5S,12R)-5,12,20-Trihydroxyicosa-6,8,10,14-tetraenoate
  • 20-Hydroxy-LTB4
  • 20-OH-Leukotriene b4
  • 20-OH-LTB4
79516-82-8

(4) Tocris Compounds for CYP4F3 Gene

Compound Action Cas Number
17-ODYA LTB omega-hydroxylase inhibitor 34450-18-5
DMOG Prolyl hydroxylase inhibitor 89464-63-1
Metyrapone 11-beta hydroxylase inhibitor 54-36-4
p-Chlorophenylalanine Tryptophan hydroxylase inhibitor 7424-00-2
genes like me logo Genes that share compounds with CYP4F3: view

Transcripts for CYP4F3 Gene

mRNA/cDNA for CYP4F3 Gene

4 REFSEQ mRNAs :
12 NCBI additional mRNA sequence :
9 Ensembl transcripts including schematic representations, and UCSC links to gene/alias where relevant :

Inhibitory RNAs for research

  • Search GeneCopoeia for shRNA, lentivirus and/or AAV clone products for CYP4F3

Alternative Splicing Database (ASD) splice patterns (SP) for CYP4F3 Gene

ExUns: 1 ^ 2a · 2b ^ 3 ^ 4 ^ 5 ^ 6 ^ 7a · 7b
SP1: - -
SP2: -
SP3: -
SP4: - -

Relevant External Links for CYP4F3 Gene

GeneLoc Exon Structure for
CYP4F3

Expression for CYP4F3 Gene

mRNA expression in normal human tissues from GTEx, Illumina, BioGPS, and SAGE for CYP4F3 Gene

mRNA expression in embryonic tissues and stem cells from LifeMap Discovery

mRNA differential expression in normal tissues according to GTEx for CYP4F3 Gene

This gene is overexpressed in Liver (x26.2), Whole Blood (x10.9), and Kidney - Cortex (x4.0).

Protein differential expression in normal tissues from HIPED for CYP4F3 Gene

This gene is overexpressed in Liver (32.9) and Gallbladder (32.1).

Integrated Proteomics: protein expression in normal tissues and cell lines from ProteomicsDB and MOPED for CYP4F3 Gene



Protein tissue co-expression partners for CYP4F3 Gene

- Elite partner

Transcriptomic regulation report from SPP (The Signaling Pathways Project) for CYP4F3

SOURCE GeneReport for Unigene cluster for CYP4F3 Gene:

Hs.106242

mRNA Expression by UniProt/SwissProt for CYP4F3 Gene:

Q08477-CP4F3_HUMAN
Tissue specificity: [Isoform CYP4F3A]: Selectively expressed in blood neutrophils and bone marrow cells. Coexpressed with CYP4F3B in prostate, ileum and trachea.

Evidence on tissue expression from TISSUES for CYP4F3 Gene

  • Blood(4.5)
  • Liver(3.8)
  • Kidney(2.8)
  • Bone marrow(2.1)
genes like me logo Genes that share expression patterns with CYP4F3: view

Primer products for research

No data available for Phenotype-based relationships between genes and organs from Gene ORGANizer for CYP4F3 Gene

Orthologs for CYP4F3 Gene

This gene was present in the common ancestor of animals.

Orthologs for CYP4F3 Gene

Organism Taxonomy Gene Similarity Type Details
Chimpanzee
(Pan troglodytes)
Mammalia CYP4F3 30
  • 99 (a)
OneToOne
LOC748117 29
  • 98.85 (n)
Dog
(Canis familiaris)
Mammalia CYP4F3 30
  • 86 (a)
OneToOne
LOC484867 29
  • 81.33 (n)
Cow
(Bos Taurus)
Mammalia LOC534967 29
  • 82.02 (n)
CYP4F3 30
  • 78 (a)
ManyToMany
Mouse
(Mus musculus)
Mammalia Cyp4f18 30
  • 80 (a)
OneToOne
Cyp4f13 29 16
  • 77.78 (n)
Rat
(Rattus norvegicus)
Mammalia Cyp4f6 29
  • 78.72 (n)
Oppossum
(Monodelphis domestica)
Mammalia -- 30
  • 65 (a)
ManyToMany
-- 30
  • 65 (a)
ManyToMany
-- 30
  • 62 (a)
ManyToMany
-- 30
  • 62 (a)
ManyToMany
-- 30
  • 58 (a)
ManyToMany
Chicken
(Gallus gallus)
Aves -- 30
  • 73 (a)
OneToMany
Lizard
(Anolis carolinensis)
Reptilia -- 30
  • 65 (a)
ManyToMany
-- 30
  • 62 (a)
ManyToMany
Zebrafish
(Danio rerio)
Actinopterygii cyp4f3 30
  • 49 (a)
OneToMany
Fruit Fly
(Drosophila melanogaster)
Insecta Cyp4d2 31
  • 38 (a)
Cyp4d14 31
  • 37 (a)
Cyp4s3 31
  • 37 (a)
Cyp4c3 31
  • 36 (a)
Cyp4d1 31
  • 36 (a)
Cyp4d8 31
  • 36 (a)
Cyp4g15 31
  • 35 (a)
Cyp4p1 31
  • 35 (a)
Cyp4p3 31
  • 35 (a)
Cyp4d20 31
  • 34 (a)
Cyp312a1 31
  • 33 (a)
Cyp4ac1 31
  • 33 (a)
Cyp4ae1 31
  • 33 (a)
Cyp4e2 31
  • 33 (a)
Cyp4e3 31
  • 33 (a)
Cyp4p2 31
  • 33 (a)
Cyp4ac3 31
  • 33 (a)
Cyp4ac2 31
  • 32 (a)
Cyp4d21 31
  • 32 (a)
Cyp4e1 31
  • 32 (a)
Cyp311a1 31
  • 31 (a)
Cyp4ad1 31
  • 30 (a)
Cyp4aa1 31
  • 30 (a)
Cyp313a3 31
  • 27 (a)
Cyp313b1 31
  • 26 (a)
Cyp4g1 31
  • 26 (a)
Cyp313a4 31
  • 26 (a)
Worm
(Caenorhabditis elegans)
Secernentea F01D5.9 31
  • 36 (a)
Y17G9B.3 31
  • 36 (a)
Y5H2B.5 31
  • 36 (a)
B0331.1 31
  • 35 (a)
Y38C9B.1 31
  • 34 (a)
Y80D3A.5 31
  • 34 (a)
F28G4.1 31
  • 33 (a)
C26F1.2 31
  • 32 (a)
Sea Squirt
(Ciona savignyi)
Ascidiacea -- 30
  • 43 (a)
ManyToMany
-- 30
  • 42 (a)
ManyToMany
-- 30
  • 42 (a)
ManyToMany
CSA.8060 30
  • 41 (a)
ManyToMany
-- 30
  • 40 (a)
ManyToMany
CSA.3998 30
  • 40 (a)
ManyToMany
-- 30
  • 39 (a)
ManyToMany
-- 30
  • 38 (a)
ManyToMany
-- 30
  • 38 (a)
ManyToMany
-- 30
  • 37 (a)
ManyToMany
-- 30
  • 37 (a)
ManyToMany
CSA.6060 30
  • 37 (a)
ManyToMany
-- 30
  • 37 (a)
ManyToMany
-- 30
  • 32 (a)
ManyToMany
-- 30
  • 32 (a)
ManyToMany
Species where no ortholog for CYP4F3 was found in the sources mined by GeneCards:
  • A. gosspyii yeast (Eremothecium gossypii)
  • Actinobacteria (Mycobacterium tuberculosis)
  • African clawed frog (Xenopus laevis)
  • African malaria mosquito (Anopheles gambiae)
  • Alicante grape (Vitis vinifera)
  • Alpha proteobacteria (Wolbachia pipientis)
  • Amoeba (Dictyostelium discoideum)
  • Archea (Pyrococcus horikoshii)
  • Baker's yeast (Saccharomyces cerevisiae)
  • Barley (Hordeum vulgare)
  • Beta proteobacteria (Neisseria meningitidis)
  • Bread mold (Neurospora crassa)
  • Chromalveolata (Phytophthora infestans)
  • Common water flea (Daphnia pulex)
  • Corn (Zea mays)
  • E. coli (Escherichia coli)
  • Filamentous fungi (Aspergillus nidulans)
  • Firmicute Bacteria (Streptococcus pneumoniae)
  • Fission Yeast (Schizosaccharomyces pombe)
  • Green Algae (Chlamydomonas reinhardtii)
  • Honey Bee (Apis mellifera)
  • K. Lactis Yeast (Kluyveromyces lactis)
  • Loblloly Pine (Pinus taeda)
  • Malaria Parasite (Plasmodium falciparum)
  • Medicago Trunc (Medicago Truncatula)
  • Moss (Physcomitrella patens)
  • Orangutan (Pongo pygmaeus)
  • Pig (Sus scrofa)
  • Platypus (Ornithorhynchus anatinus)
  • Rainbow Trout (Oncorhynchus mykiss)
  • Rice (Oryza sativa)
  • Rice Blast Fungus (Magnaporthe grisea)
  • Schistosome Parasite (Schistosoma mansoni)
  • Sea Anemone (Nematostella vectensis)
  • Sea Vase (Ciona intestinalis)
  • Sea Urchin (Strongylocentrotus purpuratus)
  • Sorghum (Sorghum bicolor)
  • Soybean (Glycine max)
  • Stem Rust Fungus (Puccinia graminis)
  • Sugarcane (Saccharum officinarum)
  • Thale Cress (Arabidopsis thaliana)
  • Tomato (Lycopersicon esculentum)
  • Toxoplasmosis (Toxoplasma gondii)
  • Trichoplax (Trichoplax adhaerens)
  • Tropical Clawed Frog (Silurana tropicalis)
  • Wheat (Triticum aestivum)

Evolution for CYP4F3 Gene

ENSEMBL:
Gene Tree for CYP4F3 (if available)
TreeFam:
Gene Tree for CYP4F3 (if available)
Aminode:
Evolutionary constrained regions (ECRs) for CYP4F3: view image
Alliance of Genome Resources:
Additional Orthologs for CYP4F3

Paralogs for CYP4F3 Gene

Variants for CYP4F3 Gene

Sequence variations, with clinical significance, from ClinVar and Humsavar, with links to dbSNP for CYP4F3 Gene

SNP ID Clinical significance and condition Chr 19 pos Variation AA Info Type
rs115569519 Benign: not provided 15,658,340(+) G/A
NM_000896.3(CYP4F3):c.1192G>A (p.Val398Ile)
MISSENSE
rs139093819 Likely Benign: not provided 15,647,318(+) C/A
NM_000896.3(CYP4F3):c.519C>A (p.Ile173=)
SYNONYMOUS
rs2460819 Benign: not provided 15,659,210(+) C/T
NM_000896.3(CYP4F3):c.1398-10C>T
INTRON
rs28371479 Likely Benign: not provided 15,650,077(+) T/Cp.Ile271Thr
NM_000896.3(CYP4F3):c.812T>C (p.Ile271Thr)
MISSENSE
rs28371536 Benign: not provided 15,650,073(+) G/Ap.Val270Ile
NM_000896.3(CYP4F3):c.808G>A (p.Val270Ile)
MISSENSE

dbSNP identifiers (rs#s) for variants without ClinVar clinical significance for CYP4F3 Gene

All consequence types are included: molecular consequences (e.g. missense, synonymous), and location-based (e.g. intron, upstream).

Structural Variations from Database of Genomic Variants (DGV) for CYP4F3 Gene

Variant ID Type Subtype PubMed ID
dgv3443n100 CNV gain 25217958
dgv3445n100 CNV gain 25217958
dgv627e199 CNV deletion 23128226
esv1597130 CNV insertion 17803354
esv2269626 CNV deletion 18987734
esv22910 CNV loss 19812545
esv2477444 CNV deletion 19546169
esv2674388 CNV deletion 23128226
esv2718235 CNV deletion 23290073
esv2718237 CNV deletion 23290073
esv3556089 CNV deletion 23714750
esv3643775 CNV loss 21293372
nsv1064684 CNV gain 25217958
nsv1066963 CNV gain 25217958
nsv1071160 CNV deletion 25765185
nsv1131406 CNV deletion 24896259
nsv470128 CNV gain 18288195
nsv578718 CNV gain 21841781
nsv954612 CNV deletion 24416366
nsv963014 CNV duplication 23825009
nsv9670 CNV loss 18304495

Variation tolerance for CYP4F3 Gene

Residual Variation Intolerance Score: 90.7% of all genes are more intolerant (likely to be disease-causing)
Gene Damage Index Score: 5.45; 71.50% of all genes are more intolerant (likely to be disease-causing)

Additional Variant Information for CYP4F3 Gene

Human Gene Mutation Database (HGMD)
CYP4F3
SNPedia medical, phenotypic, and genealogical associations of SNPs for
CYP4F3
Leiden Open Variation Database (LOVD)
CYP4F3

SNP Genotyping and Copy Number Assays for research

No data available for Polymorphic Variants from UniProtKB/Swiss-Prot for CYP4F3 Gene

Disorders for CYP4F3 Gene

MalaCards: The human disease database

(6) MalaCards diseases for CYP4F3 Gene - From: COP and GCD

Disorder Aliases PubMed IDs
trichuriasis
  • infection by trichuris trichura
neuropathy, hereditary sensory and autonomic, type ic
  • hsan1c
inflammatory bowel disease 6
  • ibd6
hereditary sensory and autonomic neuropathy type 1
  • hereditary sensory and autonomic neuropathy type i
gliosarcoma
  • glioblastoma with sarcomatous component
- elite association - COSMIC cancer census association via MalaCards

Additional Disease Information for CYP4F3

Human Genome Epidemiology Navigator
(HuGE)
Atlas
ATLAS of Genetics and Cytogenetics in Oncology and Haematology
Open Targets Platform
Open Targets Platform
genes like me logo Genes that share disorders with CYP4F3: view

No data available for UniProtKB/Swiss-Prot and Genatlas for CYP4F3 Gene

Publications for CYP4F3 Gene

  1. Human leukotriene B4 omega-hydroxylase (CYP4F3) gene: molecular cloning and chromosomal localization. (PMID: 9539102) Kikuta Y … Kusunose M (DNA and cell biology 1998) 2 3 4 22
  2. Alternative splicing determines the function of CYP4F3 by switching substrate specificity. (PMID: 11461919) Christmas P … Soberman RJ (The Journal of biological chemistry 2001) 3 4 22
  3. Expression of the CYP4F3 gene. tissue-specific splicing and alternative promoters generate high and low K(m) forms of leukotriene B(4) omega-hydroxylase. (PMID: 10409674) Christmas P … Soberman RJ (The Journal of biological chemistry 1999) 3 4 22
  4. A novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes. cDNA cloning and expression of leukotriene B4 omega-hydroxylase. (PMID: 8486631) Kikuta Y … Kusunose M (The Journal of biological chemistry 1993) 2 3 4
  5. Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects. (PMID: 19343046) Saito A … Kamatani N (Journal of human genetics 2009) 3 40

Products for CYP4F3 Gene

Sources for CYP4F3 Gene